

JRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Application of

THUROW, H.

Examiner: CORDERO GARCIA, Marcela M

Application No.: **10/632,414**

Art Unit: **1654**

Filed: **August 1, 2003**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 15, 2005

Date of Deposit

Brian Pritchett
Signature

Brian Pritchett

Title: **A Method for Purifying Preproinsulin**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

07/19/2005 SFELEKE1 00000025 181982 10632414

01 FC:1806 180.00 DA

(b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

(1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;

(2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or

(3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


Based on the new USPTO procedures, it is not required to submit copies of U.S. patents and U.S. publications for all applications filed after June 30, 2003. Therefore, a copy of the 3 (three) U.S. Patent Documents listed on the attached PTO-1449 form are not enclosed with this Information Disclosure Statement. Please note that the three U.S. patents are English language equilivances as follows:

U.S. 5,473,049 – is english equivalent to EP 0600372

U.S. 5,358,857 – is english equivalent to EP 0489780

U.S. 4,783,441 - is english equivalent to EP 0018609

Respectfully submitted,


Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2965
Telefax (908) 231-2626
Aventis Docket No. DEAV2002/0053 US NP

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

A circular stamp from the OIPE Patent and Trademark Office. The outer ring contains the text "O I P E" at the top and "PATENT & TRADEMARK OFFICE" at the bottom. The center of the stamp contains the date "JUL 19 2005" and the serial number "50-94".

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

<i>Complete if Known</i>	
Application Number	10/632,414
Filing Date	08-01-2003
First Named Inventor	THUROW
Group Art Unit	1654
Examiner Name	CORDERO GARCIA, Marcela M.
Attorney Docket Number	DEAV2002/0053 - US - NP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/632,414
Sheet	2	of	2	Filing Date	08-01-2003
				First Named Inventor	THUROW
				Group Art Unit	1654
				Examiner Name	CORDERO GARCIA, Marcela M.
				Attorney Docket Number	DEAV2002/0053 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		BRANGE, J. et. al., Toward Understanding Insulin Fibrillation, Journal of Pharmaceutical Sciences, Vol.86, No. 5 May 1997
		DE BERNARDEZ, E. et. al., Inhibition of Aggregation Side Reactions during in Vitro Protein Folding , Methods in Enzymology, Vol. 39, pp. 217-236 (1999)
		KEMMLER, W., et. al. , Studies on the Conversion of Proinsulin to Insulin, The Journal of Biological Chemistry Vol.246, No. 22 pp.6786-6791
		RATNER, R., et. al., Persistent Cutaneous Insulin Allergy Resulting from High-Molecular-Weight Insulin Aggregates , Diabetes, Vol. 39, (1990) pp.728-733
		STEINER, D.F., Isolation and Properties of PRoinsulin, Intermediate Forms, and Other Minor Components from Crystalline Bovine Insulin, Diabetes, Vol.17, No.12 pp. 725-736 (1968)
		THUROW,H., Stabilisation of Dissolved proteins against Denaturation at Hydrophobic Interfaces, Diabetologia (1984), Vol.27, pp.212-218

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

THUROW, H.

Examiner: CORDERO GARCIA, Marcella M.

Application No.: **10/632,414**

Art Unit: **1654**

Filed: **August 1, 2003**

Certificate of Mailing or Transmission
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop address below, or being facsimile transmitted to the USPTO, on the date indicated below.
Date of Deposit July 15, 2005
Printed Name of Person Signing Certificate Brian Pritchett
Signature Brian Pritchett

Title: **A Method for Purifying Preproinsulin**


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. **18-1982** in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**2965**
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0053 US NP